• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Neuroimmunology: Official Bulletin of the Research Committee on Neuroimmunology of the World Federation of Neurology >Combined treatment with minocycline and prednisone attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice
【24h】

Combined treatment with minocycline and prednisone attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice

机译：米诺环素和泼尼松联合治疗可减轻C57 BL / 6小鼠实验性自身免疫性脑脊髓炎

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

There has been enormous progress in the treatment of multiple sclerosis (MS) in recent years, but further improvement in therapy is still required because not all patients respond optimally to existing treatments. Increasing evidence has demonstrated that combination therapies produce a more favorable clinical outcome than monotherapy in MS treatment. Minocycline is effective in experimental autoimmune encephalomyelitis (EAE), and is a promising candidate for future MS medication. Glucocorticosteroids (GCS) belong to the most potent immunosuppressive drugs and are the mainstay for treatment of acute relapses in MS. In this study, we tested whether the combination of minocycline and prednisone (a synthetic GCS) at suboptimal doses could produce synergistic effects in EAE. Our findings showed that the combination of these two drugs functioned better than when they were individually administered in EAE mice, as evidenced by decreased clinical scores, reduced inflammation and demyelination, and improved magnetic resonance imaging outcomes. Further studies revealed that the combined treatment prevented the reduction of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) mRNA expression in cerebral cortex of EAE mice. In conclusion, our findings indicated that this combination therapy suppressed disease severity of EAE partially through blocking the downregulation of neurotrophic factor expression, suggesting that the combination of minocycline and prednisone could be a novel treatment in MS.
机译：近年来，多发性硬化症（MS）的治疗取得了巨大进展，但由于并非所有患者对现有治疗均能产生最佳反应，因此仍需要进一步改善治疗。越来越多的证据表明，在MS治疗中，联合疗法比单一疗法产生更好的临床结果。米诺环素对实验性自身免疫性脑脊髓炎（EAE）有效，并且是未来MS药物的有希望的候选者。糖皮质激素（GCS）属于最有效的免疫抑制药物，是治疗MS急性复发的主要手段。在这项研究中，我们测试了次优剂量的米诺环素和强的松（一种合成的GCS）的组合能否在EAE中产生协同作用。我们的发现表明，这两种药物的组合比分别在EAE小鼠中单独给药时具有更好的功能，如临床评分降低，炎症和脱髓鞘减少以及磁共振成像结果改善所证明。进一步的研究表明，联合治疗可防止EAE小鼠大脑皮层中脑源性神经营养因子（BDNF）和神经生长因子（NGF）mRNA表达的降低。总之，我们的发现表明，这种联合疗法部分通过阻止神经营养因子表达的下调来部分抑制EAE的疾病严重性，这表明米诺环素和泼尼松联合可能是MS的一种新型治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号